Vue.component('iop-la-overview', { template: '
The percentage of individuals ≥18 years of age with ≥1 initial opioid prescriptions for long-acting or extended-release opioids.
' + 'A lower rate indicates better performance.
' + 'Intended Use
' + 'Performance measurement for health plans.
' + 'Data Sources
' + 'Prescription and medical claims data.
' + 'Denominator
' + 'Individuals ≥18 years of age with a negative medication history for any opioid medication during the 90-day lookback period.
' + 'Exclusions
' + 'Hospice, cancer, and sickle cell disease.
' + 'Numerator
' + 'Individuals from the denominator with ≥1 prescription claims for a long-acting or extended-release (LA/ER) opioid within any opioid initiation period.
' + '' +
'Opioid misuse, addiction, and overdose are a public health crisis affecting social and economic welfare in the United States.' +
'
' +
'When initiating opioid therapy, starting with long-acting/extended-release (LA/ER) opioids is associated with an increased risk of continued opioid use' +
'
' +
'Published studies support the CDC recommendation to start therapy with immediate-release opioids instead of LA/ER opioids. In 2017, Shah and colleagues examined the relationship between initial opioid prescription characteristics and the probability of opioid discontinuation in a retrospective cohort study using claims data from a nationally representative database of commercially insured patients.' +
'
' +
'Aligned with CDC recommendations and published evidence, this performance measure evaluates the percentage of individuals ≥18 years of age with ≥1 initial opioid prescriptions for LA/ER opioids. Patients with cancer diagnoses and those receiving hospice care are excluded from the measures because of their unique therapeutic goals, ethical considerations, opportunities for medical supervision, and balance of risks and benefits.' +
'
Yes, both individuals in hospice and with a cancer diagnosis are excluded from these measures.
' + 'Other exclusions such as sickle cell disease were considered and voted on by the Measure Update Panel (MUP) and Quality Metric Expert Panel (QMEP) for our other opioid-related measures. PQA also sought out expert opinion on these exclusions.
' + 'Most measures have the risk of unintended consequences—such as use of cash claims to avoid detection of inappropriate initial opioid prescribing. However, these risks must be balanced with the potential for improved clinical outcomes that are expected from the use of these measures when used as intended.
' + 'PQA intends to monitor the use of these measures in accountability programs. Additionally, we will continue to refine the measures with the input of its users and through our measure update process.